In addition to genomic subgrouping and the number of BPs, specific tumor genetic aberrations, including ALK mutation/amplification [37,42], abnormal telomere maintenance mechanisms (TERT rearrangements, the alternative lengthening of telomeres, and high TERT expression) [24,25], ATRX alterations [43], and mutations in TP53/RAS/MAPK signaling pathway-related genes [24,44,45] have been shown to correlate with patient prognosis. The gene discussed is ALK; the disease is Bartsocas-Papas syndrome 1.